Pharma

Your Article Summary

See Latest Articles

Teva Completes Enrollment in Second Oral Laquinimod Phase III MS Clinical Trial
Active Biotech, 06/26/09

Teva Pharmaceutical Industries Ltd. and Active Biotech announced completion of patient enrollment for the second pivotal Phase III clinical trial, BRAVO, evaluating the novel, oral once-daily immunomodulating compound, laquinimod, for the treatment of relapsing-remitting multiple sclerosis. BRAVO is a global clinical trial designed to evaluate the efficacy, safety and tolerability of laquinimod versus placebo, and to provide risk-benefit data for laquinimod versus a currently available injectable treatment, Avonex.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
New England Journal of Medicine, 11/20/09

Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest: A Randomized Trial
JAMA, 11/25/09

Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain
Abbott, 11/16/09

See All of Drug Trials